The company is at the forefront of the global fight against infectious diseases with the goal of developing new treatments to prevent death and improve lives.
Appili Therapeutics (TSX: APLI) is an infectious disease biopharmacy company whose mission is to resolve life-threatening infectious diseases. The company is part of a consortium sponsoring late-stage clinical trials evaluating the antiviral drug Avigan / Reeqonus for the global treatment and prevention of COVID-19.
Financing revenue evaluates oral antivirals for the treatment of mild to moderate COVID-19, provides this highly needed drug, and hopefully changes the course of this pandemic, the company’s number one Useful for 3-phase PRESECO trials.
In the afternoon trading, stock prices rose nearly 3%.
Funded biopharmacy company stock
http://www.baystreet.ca/articles/stockstowatch.aspx?id=11482 Funded biopharmacy company stock